Clovis (CLVS) options active on FDA accepts rucaparib NDA for priority review
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Clovis Oncology (NASDAQ: CLVS) September 25 calls and puts are active on total call volume of 13K contracts (8K puts) after FDA accepts rucaparib NDA for priority review. September call option implied volatility is at 99, October is at 101, January is at 98; compared to its 52-week range of 60 to 219.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stocks with call price movement; LC TWTR
- Option volume flows
- AK Steel (AKS) October weekly volatility increases on more puts than calls into Q3
Create E-mail Alert Related CategoriesOptions, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!